Tesaro’s Rolapitant Hits Primary Endpoints, But Still Disappoints
This article was originally published in The Pink Sheet Daily
The oncology company’s nausea treatment was successful in late-stage trials, but Tesaro may have trouble differentiating the drug once it reaches the market due to a lack of evidence that it can compete with the current standard of care.
You may also be interested in...
Tesaro’s three-drug oncology program, including its lead NK-1 product for chemo-induced nausea and vomiting, is boosted by a recent raise from the public markets.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.